HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Immix Biopharma, Inc.

Contributing Author

Recent Articles by Immix Biopharma, Inc.

Jan-28
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 IMMX GlobeNewswire
Dec-09
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants IMMX GlobeNewswire
Dec-07
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants IMMX GlobeNewswire
Dec-07
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
Nov-12
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch IMMX GlobeNewswire
Nov-03
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 IMMX GlobeNewswire
Oct-14
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference IMMX GlobeNewswire
Oct-06
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting IMMX GlobeNewswire
Oct-01
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference IMMX GlobeNewswire
Sep-18
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 IMMX GlobeNewswire
Sep-11
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors IMMX GlobeNewswire
Sep-08
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang IMMX GlobeNewswire
Aug-25
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference IMMX GlobeNewswire
Aug-06
Immix Biopharma Announces Other Serious Diseases Strategy IMMX GlobeNewswire
Jul-11
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion IMMX GlobeNewswire
Jul-07
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
Jun-06
Immix Biopharma Attends FDA CEO Forum in Washington DC IMMX GlobeNewswire
Jun-03
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
May-23
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 IMMX GlobeNewswire
May-22
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
May-21
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.